Murine leukemia virus glycosylated Gag blocks apolipoprotein B editing complex 3 and cytosolic sensor access to the reverse transcription complex

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 22, 2013, Pages 9078-9083

  Stavrou, Spyridon ^a   Nitta, Takayuki ^b   Kotla, Swathi ^a   Ha, Dat ^b   Nagashima, Kunio ^c   Rein, Alan R ^d   Fan, Hung ^b   Ross, Susan R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Intrinsic Immunity; Trex1; Virus Restriction Factors

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN B EDITING COMPLEX 3; GAG PROTEIN; GLYCOSYLATED GAG PROTEIN; GLYCOSYLATED PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOSOL; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MURINE LEUKEMIA VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RETROVIRUS INFECTION; REVERSE TRANSCRIPTION; VIRION; VIRUS CORE; VIRUS INFECTIVITY; VIRUS ISOLATION;

INTRINSIC IMMUNITY; TREX1; VIRUS RESTRICTION FACTORS;

ANIMALS; BLOTTING, WESTERN; CYTIDINE DEAMINASE; DNA PRIMERS; GENE PRODUCTS, GAG; GLYCOSYLATION; HOST-PATHOGEN INTERACTIONS; LEUKEMIA VIRUS, MURINE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; NIH 3T3 CELLS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION;

MIRIDAE; MURINE LEUKEMIA VIRUS; MUS;

EID: 84878429046     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1217399110     Document Type: Article

References (53)

1. Edwards SA, Fan H (1979) gag-Related polyproteins of Moloney murine leukemia virus: evidence for independent synthesis of glycosylated and unglycosylated forms. J Virol 30(2):551-563.
2. Evans LH, Dresler S, Kabat D (1977) Synthesis and glycosylation of polyprotein precursors to the internal core proteins of Friend murine leukemia virus. J Virol 24(3):865-874.
3. Prats AC, De Billy G,Wang P, Darlix JL (1989) CUG initiation codon used for the synthesis of a cell surface antigen coded by the murine leukemia virus. J Mol Biol 205(2):363-372.
4. Fujisawa R, McAtee FJ, Zirbel JH, Portis JL (1997) Characterization of glycosylated Gag expressed by a neurovirulent murine leukemia virus: Identification of differences in processing in vitro and in vivo. J Virol 71(7):5355-5360.
5. Edwards SA, Fan H (1980) Sequence relationship of glycosylated and unglycosylated gag polyproteins of Moloney murine leukemia virus. J Virol 35(1):41-51.
6. Pillemer EA, Kooistra DA, Witte ON, Weissman IL (1986) Monoclonal antibody to the amino-terminal L sequence of murine leukemia virus glycosylated gag polyproteins demonstrates their unusual orientation in the cell membrane. J Virol 57(2):413-421.
7. Fujisawa R, McAtee FJ, Favara C, Hayes SF, Portis JL (2001) N-terminal cleavage fragment of glycosylated Gag is incorporated into murine oncornavirus particles. J Virol 75(22):11239-11243.
8. Kolokithas A, et al. (2010) The glycosylated Gag protein of a murine leukemia virus inhibits the antiretroviral function of APOBEC3. J Virol 84(20):10933-10936.
9. Fan H, Chute H, Chao E, Feuerman M (1983) Construction and characterization of Moloney murine leukemia virus mutants unable to synthesize glycosylated gag polyprotein. Proc Natl Acad Sci USA 80(19):5965-5969.
10. Corbin A, Prats AC, Darlix JL, Sitbon M (1994) A nonstructural gag-encoded glycoprotein precursor is necessary for efficient spreading and pathogenesis of murine leukemia viruses. J Virol 68(6):3857-3867.
11. Schwartzberg P, Colicelli J, Goff SP (1983) Deletion mutants of Moloney murine leukemia virus which lack glycosylated gag protein are replication competent. J Virol 46(2):538-546.
12. Chun R, Fan H (1994) Recovery of Glycosylated gag Virus from Mice Infected with a Glycosylated gag-Negative Mutant of Moloney Murine Leukemia Virus. J Biomed Sci 1(4):218-223.
13. Low A, et al. (2007) Mutation in the glycosylated gag protein of murine leukemia virus results in reduced in vivo infectivity and a novel defect in viral budding or release. J Virol 81(8):3685-3692.
14. Nitta T, Kuznetsov Y, McPherson A, Fan H (2010) Murine leukemia virus glycosylated Gag (gPr80gag) facilitates interferon-sensitive virus release through lipid rafts. Proc Natl Acad Sci USA 107(3):1190-1195.
15. Pizzato M (2010) MLV glycosylated-Gag is an infectivity factor that rescues Nefdeficient HIV-1. Proc Natl Acad Sci USA 107(20):9364-9369.
16. Cullen BR (2006) Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. J Virol 80(3):1067-1076.
17. Münk C, Willemsen A, Bravo IG (2012) An ancient history of gene duplications, fusions and losses in the evolution of APOBEC3 mutators in mammals. BMC Evol Biol 12:71.
18. Holmes RK, Koning FA, Bishop KN, Malim MH (2007) APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. J Biol Chem 282(4):2587-2595.
19. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH (2008) APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 4(12):e1000231.
20. Gillick K, et al. (2013) Suppression of HIV-1 infection by APOBEC3 proteins in primary human CD4(+) T cells is associated with inhibition of processive reverse transcription as well as excessive cytidine deamination. J Virol 87(3):1508-1517.
21. MacMillan AL, Kohli RM, Ross SR (2013) APOBEC3 inhibition ofMMTV infection: The role of cytidine deamination versus inhibition of reverse transcription. J Virol 87:4808-4817.
22. Goila-Gur R, Strebel K (2008) HIV-1, APOBEC, and intrinsic immunity. Retrovirology 5:51.
23. Koning FA, Goujon C, Bauby H, Malim MH (2011) Target cell-mediated editing of HIV-1 cDNA by APOBEC3 proteins in human macrophages. J Virol 85(24):13448-13452.
24. Berger G, et al. (2011) APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathog 7(9):e1002221.
25. Vetter ML, D'Aquila RT (2009) Cytoplasmic APOBEC3G restricts incoming Vif-positive human immunodeficiency virus type 1 and increases two-long terminal repeat circle formation in activated T-helper-subtype cells. J Virol 83(17):8646-8654.
26. Okeoma CM, Lovsin N, Peterlin BM, Ross SR (2007) APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 445(7130):927-930.
27. Santiago ML, et al. (2008) Apobec3 encodes Rfv3, a gene influencing neutralizing antibody control of retrovirus infection. Science 321(5894):1343-1346.
28. Low A, et al. (2009) Enhanced replication and pathogenesis of Moloney murine leukemia virus in mice defective in the murine APOBEC3 gene. Virology 385(2):455-463.
29. Langlois MA, Kemmerich K, Rada C, Neuberger MS (2009) The AKV murine leukemia virus is restricted and hypermutated by mouse APOBEC3. J Virol 83(22):11550-11559.
30. Takeda E, et al. (2008) Mouse APOBEC3 restricts friend leukemia virus infection and pathogenesis in vivo. J Virol 82(22):10998-11008.
31. Okeoma CM, Petersen J, Ross SR (2009) Expression of murine APOBEC3 alleles in different mouse strains and their effect on mouse mammary tumor virus infection. J Virol 83(7):3029-3038.
32. Li J, et al. (2012) Two genetic determinants acquired late in mus evolution regulate the inclusion of exon 5, which alters mouse APOBEC3 translation efficiency. PLoS Pathog 8(1):e1002478.
33. Browne EP, Littman DR (2008) Species-specific restriction of apobec3-mediated hypermutation. J Virol 82(3):1305-1313.
34. Rulli SJ, Jr., et al. (2008) Interactions of murine APOBEC3 and human APOBEC3G with murine leukemia viruses. J Virol 82(13):6566-6575.
35. Sanchez-Martinez S, et al. (2012) Studies on the restriction of murine leukemia viruses by mouse APOBEC3. PLoS ONE 7(5):e38190.
36. Bogerd HP, Tallmadge RL, Oaks JL, Carpenter S, Cullen BR (2008) Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism. J Virol 82(23):11889-11901.
37. Zielonka J, et al. (2009) Restriction of equine infectious anemia virus by equine APOBEC3 cytidine deaminases. J Virol 83(15):7547-7559.
38. Stremlau M, et al. (2006) Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5alpha restriction factor. Proc Natl Acad Sci USA 103(14):5514-5519.
39. Perron MJ, et al. (2007) The human TRIM5alpha restriction factor mediates accelerated uncoating of the N-tropic murine leukemia virus capsid. J Virol 81(5):2138-2148.
40. Okeoma CM, et al. (2009) Induction of APOBEC3 in vivo causes increased restriction of retrovirus infection. J Virol 83(8):3486-3495.
41. Pfeiffer JK, Topping RS, Shin NH, Telesnitsky A (1999) Altering the intracellular environment increases the frequency of tandem repeat deletion during Moloney murine leukemia virus reverse transcription. J Virol 73(10):8441-8447.
42. Roa A, et al. (2012) RING domain mutations uncouple TRIM5a restriction of HIV-1 from inhibition of reverse transcription and acceleration of uncoating. J Virol 86(3):1717-1727.
43. Hulme AE, Perez O, Hope TJ (2011) Complementary assays reveal a relationship between HIV-1 uncoating and reverse transcription. Proc Natl Acad Sci USA 108(24):9975-9980.
44. Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieberman J (2010) The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 11(11):1005-1013.
45. Stetson DB, Ko JS, Heidmann T, Medzhitov R (2008) Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell 134(4):587-598.
46. Harris RS, Hultquist JF, Evans DT (2012) The restriction factors of human immunodeficiency virus. J Biol Chem 287(49):40875-40883.
47. Derse D, Hill SA, Princler G, Lloyd P, Heidecker G (2007) Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proc Natl Acad Sci USA 104(8):2915-2920.
48. Ooms M, Krikoni A, Kress AK, Simon V, Münk C (2012) APOBEC3A, APOBEC3B, and APOBEC3H haplotype 2 restrict human T-lymphotropic virus type 1. J Virol 86(11): 6097-6108.
49. Okimoto MA, Fan H (1999) Identification of directly infected cells in the bone marrow of neonatal moloney murine leukemia virus-infected mice by use of a moloney murine leukemia virus-based vector. J Virol 73(2):1617-1623.
50. Tsuji-Kawahara S, et al. (2010) Persistence of viremia and production of neutralizing antibodies differentially regulated by polymorphic APOBEC3 and BAFF-R loci in friend virus-infected mice. J Virol 84(12):6082-6095.
51. Wang X, et al. (2012) The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication. J Virol 86(7):3777-3786.
52. Okeoma CM, Huegel AL, Lingappa J, Feldman MD, Ross SR (2010) APOBEC3 proteins expressed in mammary epithelial cells are packaged into retroviruses and can restrict transmission of milk-borne virions. Cell Host Microbe 8(6):534-543.
53. Warrilow D, et al. (2008) Cell factors stimulate human immunodeficiency virus type 1 reverse transcription in vitro. J Virol 82(3):1425-1437.